The financials
TransMedics Group, Inc. by the numbers
TransMedics Group, Inc. (TMDX) reported revenue of $174M in Q1 2026 (quarter ended March 31, 2026), up 21% from the same quarter a year earlier. That came with a gross margin of 58% and net income of $7.3M (4.2% of revenue). For the full year FY2025, revenue was $605M (+37% year on year) and net income $190M. Its largest product in 2026-Q2 was Liver Product at $148M, 80% of the disclosed total, just ahead of Heart Product at 18%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $174M | $144M | +21% |
| Gross profit | $101M | $88M | +15% |
| Operating income | $13M | $27M | −52% |
| Net income | $7.3M | $26M | −72% |
| Diluted EPS | $0.20 | $0.70 | −71% |
| Product | Revenue | Share |
|---|---|---|
| Liver Product | $148M | 80% |
| Heart Product | $33M | 18% |
| Lung Product | $2.3M | 1.2% |
| Service Unrelated To OCS Transplant | $1.0M | 0.5% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q2 2026Total $184.6M (+9.7%)
Liver Product grew +28% year on yearLung Product -46% year on year
Segment Latestquarter on quarteryear on year
- Liver Product$148.0M$148.0MQoQ +6.5%year on year +28%+6.5%+28%
- Heart Product$33.4M$33.4MQoQ +29%year on year +3.8%+29%+3.8%
- Lung Product$2.3M$2.3MQoQ +2.5%year on year -46%+2.5%-46%
- Service Unrelated To OCS Transplant$1.0M$1.0MQoQ -23%year on year 0.00%-23%0.00%